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Abstract
Background: Particulate matter (PM) is one of the principal causes of human respiratory disabilities resulting from
air pollution. Animal models have been applied to discover preventive and therapeutic drugs for lung diseases
caused by PM. However, the induced severity of lung injury in animal models using PM varies from study to study
due to disparities in the preparation of PM, and the route and number of PM administrations. In this study, we
established an in vivo model to evaluate PM-induced lung injury in mice.
Results: PM dispersion was prepared using SRM2975. Reactive oxygen species were increased in MLE 12 cells
exposed to this PM dispersion. In vivo studies were conducted in the PM single challenge model, PM multiple
challenge model, and PM challenge with ovalbumin-induced asthma using the PM dispersion. No histopathological
changes were observed in lung tissues after a single injection of PM, whereas mild to moderate lung inflammation
was obtained in the lungs of mice exposed to PM three times. However, fibrotic changes were barely seen, even
though transmission electron microscopy (TEM) studies revealed the presence of PM particles in the alveolar
macrophages and alveolar capillaries. In the OVA-PM model, peribronchial inflammation and mucous
hypersecretion were more severe in the OVA+PM group than the OVA group. Serum IgE levels tended to increase
in OVA+PM group than in OVA group.
Conclusions: In this study, we established a PM-induced lung injury model to examine the lung damage induced
by PM. Based on our results, repeated exposures of PM are necessary to induce lung inflammation by PM alone. PM
challenge, in the presence of underlying diseases such as asthma, can also be an appropriate model for studying
the health effect of PM.
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Background
Air pollution refers to environmental pollution in which
various pollutants (such as factory smoke, car exhaust,
etc.) are dispersed in the atmosphere due to human ac-
tivities [1]. Globally, more than 1 billion people inhale
harmful indoor or outdoor air contaminated with toxic
gases and particulate matters from cigarette smoke and
biomass fuel [2], and 7 million people are reported to
die due to such air pollution [3]. Furthermore, disabil-
ities and deaths caused by air pollution result in signifi-
cant economic losses, amounting to more than 5 trillion
US dollars worldwide [4].
Among the air pollutants, fine particulate matter (PM)
is a major risk factor that causes acute and/or chronic
diseases in human organs, particularly the cardiovascular
system [5], hepatobiliary system [6], gastrointestinal tract
[7], and respiratory system [8]. PM comprises both solid
and liquid particles with constantly changing size and
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chemical composition, and are classified depending on
their diameter. PM of diameter equal to or less than
2.5 μm (PM2.5) penetrates deep into the alveoli along
the airway, and is also able to traverse the alveolar
wall into the blood vessels, inducing severe lung in-
flammation [9].
Several in vitro and in vivo studies have been con-
ducted over the past few decades to identify the mo-
lecular mechanisms of lung diseases associated with
PM exposure, and to develop preventive and thera-
peutic drugs. It has recently been suggested that the
main event of PM-induced lung damage is intracellu-
lar ROS generation by PM, which subsequently stimu-
lates several inflammatory signals, including the
MAPK signaling pathway and NF-κB pathway, result-
ing in cellular injury [10–12].
As animal experiments, PM-induced lung injury
mouse models have been attempted by applying various
methods of PM delivery into the lungs [13] including in-
halation, intratracheal instillation, endotracheal injection,
and nasal inoculation. However, the severity of lung dis-
ease caused by PM differs, depending on the mode of
administration. Moreover, studies have differed on the
dosing of PM using the same administration method;
some studies treated a single dose of PM, whereas others
administered PM several times to induce lung inflamma-
tion [14].
The method of preparing PM dispersions also differed
between researchers, depending on the solvents used,
the number and duration of sonicating steps, and the
presence of additive [15]. In addition, some studies have
reported that PM alone is difficult to induce sufficient
lung disease, but exposure to PM exacerbates lung injury
in the presence of underlying diseases such as COPD
[16] and asthma [17]. Therefore, there is a requirement
to establish an in vivo model that is easy to perform, and
can confirm lung damage caused by PM.
In the current study, we compared the various
methods applied for preparing PM dispersions, and per-
formed in vivo studies with differing schedules. Our ex-
periments include both PM single and multi-challenge
models, and also PM challenge in the OVA-induced air-
way inflammation model. This enabled us to establish a
practical way to induce lung injury associated with PM
in mice.
Results
Preparation and size analysis of PM dispersions
To determine whether differences in biochemical prop-
erties are dependent on solvents, we dispersed SRM2975
in DMSO or PBS, and sonicated the suspensions using a
bath sonicator (PM-DMSO and PM-PBS, respectively).
MLE 12 cells were subsequently exposed to PM-DMSO
or PM-PBS, and the intracellular reactive oxygen species
(ROS) was measured by flow cytometry. Higher ROS
levels were obtained in MLE 12 cells exposed to PM-
PBS, as compared to PM-DMSO (data not shown). Size
analysis for the two suspensions revealed particle sizes of
PM-DMSO and PM-PBS to be 657.0 ± 43.1 nm and
413.5 ± 38.5 nm, respectively (mean ± standard error of
mean (SEM)). PM-PBS was sonicated again with a probe
sonicator to reduce the particle size (Fig. 1A, PM-a).
Next, we investigated for differences depending on the
presence of additives: PM-a was mixed with 0.05% (v/v)
tween 80 (Fig. 1A, PM-b). Size analysis of PM-a and
PM-b (Fig. 1B) revealed that although the polydispersity
index (P.I.) of PM-b was higher than P.I. of PM-a, the
mean diameter of PM-b obtained (259.5 nm) was smaller
than diameter of PM-a (314.6 nm).
Biological characteristics of PM-a and PM-b in MLE 12
cells
MLE 12 cells were exposed to PM-a or PM-b for 30
min, following which levels of intracellular ROS were
measured. Compared to their respective control group,
the ROS production was increased by about 10% in PM-
a exposed MLE cells, whereas a 4-fold increase was de-
termined in MLE cells treated with PM-b (Fig. 2A). This
result indicates that PM-b is a more harmful stimulus
than PM-a. To confirm that PM-b can induce cellular
signaling related to injuries, MLE 12 cells were exposed
to PM-b for indicated varying durations, and protein ex-
pression levels related to inflammatory signals or au-
tophagy were determined by Western blotting (Fig. 2B).
In short time exposures, the expression levels of HO-1
and COX-2 were time-dependently increased following
PM-b exposure in MLE 12 cells, with minimal change in
the pSTAT3 (Y705) and pP65 (S536) expressions. Con-
sidering the autophagy activities, the conversion of LC3-
I to LC3-II showed a time-dependent increase after PM-
b exposure, as compared to the control (Fig. 2B, left
panel). Similar results were observed in MLE 12 cells ex-
posed to PM-b for longer time (Fig. 2B, right panel).
Based on the results of these in vitro experiments, we
initiated further in vivo animal studies using PM-b.
Pulmonary histopathology in PM single challenge model
To explore the effect of duration from single dose of PM
to autopsy, intratracheal instillation of PM-b was per-
formed for ICR mice at day 0. Mice were divided into
two groups: mice euthanized at day 7 (n = 5) or day 14
(n = 5) (Fig. 3A). On the day of autopsy, the lungs were
harvested and histologically evaluated by subjecting the
lung tissue to HE staining. PM-b alone and alveolar
macrophages containing PM-b were detected, but there
were no observable features related to lung injury such
as thickened alveolar walls and infiltration of inflamma-
tory cells. Similarly, MT and SR staining revealed no
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significant fibrotic changes in the lung (Fig. 3B, above).
And also, there were no obvious histological differences
between day 7 and day 14 (Fig. 3B, below).
Pulmonary histopathology in the PM multiple challenges
model
In order to verify that multiple administrations of PM-b
induces pulmonary inflammation, ICR mice were intra-
tracheally injected with PM-b three times, and autopsy
was performed 3 days or 3 weeks after the last injection
(Fig. 4A). HE staining of the lungs harvested at day 10
revealed an increased number of PM-b depositions com-
pared to lungs examined in the single challenge model.
Moreover, mild inflammation was also observed, as
compared to the PBS control group. Nevertheless, sig-
nificant histopathological changes related to lung fibrosis
were not detected on MT and SR staining (Fig. 4B). On
day 28 after the last injection, HE staining revealed mod-
erate inflammation and an increased number of PM-b
depositions in the lungs of PM-b exposed mice, but
there was no evidence of pulmonary fibrosis on MT and
SR staining (Fig. 4C).
Transmission Electron Microscopy (TEM) images of the
lung treated with PM-b
Transmission electron microscopic images were taken to
examine for phagocytosis of PM-b by alveolar macro-
phages. After three administrations of PM-b (Fig. 4A,
day 28), several vacuoles containing PM-b were observed
in the alveolar macrophages, and PM-b depositions were
also observed in the alveolar capillaries (Fig. 5).
Histopathological changes and serum IgE ELISA in the
OVA-PM model
To determine the effect of PM-b exposure on mice with
lung inflammation induced by OVA, we conducted the
OVA-PM model according to the following experimen-
tal scheme (Fig. 6A). To induce pulmonary inflammation
Fig. 1 Preparation and size analysis of particulate matter dispersions. A Scheme of producing PM dispersions. Two PM dispersions (PM-a
and PM-b) were prepared, following the procedures described. B Particle sizes of PM-a and PM-b were analyzed. Size distributions of each PM
dispersion are shown as graphs. Polydispersity index and mean diameter of particles are described (mean ± standard error of mean)
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using OVA, mice were sensitized with intraperitoneal in-
jections of OVA complexed with Al(OH)3, and chal-
lenged with intranasal inoculation of 2% OVA solution.
In the lung tissues obtained from the OVA group, HE
staining revealed infiltration of inflammatory cells in the
peribronchial regions, and also an increased number of
PAS positive cells, as compared to that of the control
group. Moreover, the number of infiltrated cells and
PAS positive cells were greater in the OVA+PM group,
as compared to the OVA group (Fig. 6B). To compare
the allergic reaction among groups, serum IgE levels
were determined by ELISA. Compared to the control
groups, serum IgE levels were elevated in both the OVA
and OVA+PM groups. Although not significant, the
level tended to increase in response to PM-b exposure
(Fig. 6C).
Discussion
The introduction of various aerosol pollutants into the
air results in environmental air pollution, and 7 million
people die annually due to inhalation of toxic gases
and PM produced by combustion of cigarettes and
biomass fuels. In addition, economic losses amounting
to trillions of US dollars have been incurred in rela-
tion to the deaths caused by air pollution. PM, one of
the main risk factors of air pollution, enters the lower
respiratory tract and results in lung inflammation. Es-
pecially, PM2.5 is able to penetrate into the blood
vessels and cause a variety of diseases across organs
in humans.
For the past few decades, in vitro and in vivo studies
have been conducted to identify the molecular biological
mechanisms of diseases caused by PM, and to establish
preventive measures or develop treatments. The PM-
induced lung disease model in mice has been widely ap-
plied in these researches, but each study has a different
degree of inflammation or fibrosis with the same admin-
istration method and dosing schedule. In the current
study, animal experiments were performed using several
methods, with the intention to establish a practical
Fig. 2 Effects of PM-a and PM-b on the biological characteristics of MLE 12 cells. A Intracellular reactive oxygen species are measured by
flow cytometry. MLE 12 cells were treated with PM-a (100 μg/ml) or PM-b (100 μg/ml) for 30 min. Con-a and con-b indicate the control groups of
PM-a and PM-b, respectively. B Protein expressions related to inflammatory signals and autophagy pathway were detected by Western blotting.
MLE 12 cells were treated with PM-b (100 μg/ml) for the indicated hours
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protocol to reproduce PM-induced lung damage in
humans.
Prior to animal experiments, we established a proced-
ure for making PM dispersion, since varied methods had
been used by different researchers. Recent studies have
suggested that PM induces cellular damage through
ROS in a variety of cells, such as pneumocytes [12],
macrophages [18], and endothelial cells [19]. We there-
fore focused on ROS generation induced by the PM dis-
persion prepared in our laboratory.
Considering that the compositional variation of PM
depends on the origin of the collected PM, we con-
ducted the in vitro and in vivo experiments using
SRM2975 as a reference material. SRM2975 was first
dispersed in either DMSO or PBS to explore the varia-
tions produced by different solvents. Intracellular ROS
level was higher in MLE 12 cells treated with PM-PBS
than with PM-DMSO exposure. Moreover, the mean
particle size of PM-PBS was also smaller than that of
PM-DMSO (413.5 nm and 657.0 nm, respectively). These
sizes were small enough to meet the PM2.5 criteria, but
larger than the reported size in other studies using
SRM2975 [20–22]. We therefore prepared another PM
dispersion containing smaller size of particles by sonicat-
ing the PM-PBS (Fig. 1A, PM-a). One study suggested
that PM dispersions with stabilizers such as human
serum albumin and tween 80 are stable without forming
coarse agglomerates [15]. Following this concept, PM-b
was prepared by mixing PM-a with tween 80 (Fig. 1A,
PM-b).
Size analysis of PM-a and PM-b revealed that PM-b
had a smaller mean diameter than PM-a (Fig. 1B).
Higher ROS was produced in MLE 12 cells treated with
PM-b than with PM-a (Fig. 2A), thereby confirming that
smaller particles cause a more severe lung disease [23].
Furthermore, Western blotting analysis confirmed an in-
crease in protein expression levels of inflammatory sig-
nals and autophagic activities after PM-b exposure in
MLE 12 cells (Fig. 2B). Based on the results of induced
intracellular ROS, increased inflammatory signals, and
increased autophagy activities, subsequent animal exper-
iments were conducted using PM-b.
Considering the exposure route of PM in humans, the
inhalation method may produce similar results with the
consequences observed in humans exposed to PM [24].
However, since it is challenging to perform the
Fig. 3 Histopathological changes after single challenge of PM-b. A Experimental schedule. PM-b was intratracheally injected at day 0, and
mice were euthanized on days 7 (n = 5) and 14 (n = 5). B Representative images of the lung of mice on days 7 and 14. Pulmonary
histopathological changes after single challenge of PM-b were evaluated by three different types of staining (HE: Hematoxylin-Eosin staining; MT:
Masson’s Trichrome staining; SR: Sirius Red staining). Scale bar: 100 μm
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inhalation method due to the need for dedicated equip-
ment (such as aerosol generator and ventilating system),
the current study applied the intratracheal instillation
method to deliver PM into the lung.
The single challenge model was performed in mice to
induce lung inflammation using a single dose of PM-b.
Mice exposed to PM-b were sacrificed at 7 days or 14
days after PM-b exposure, to evaluate differences in lung
injury depending on the retention period of PM-b in the
body (Fig. 3A). At 7 days after i.t. instillation of PM-b,
the PM-b itself and alveolar macrophages containing
PM-b were observed in the lungs. However, neither lung
Fig. 4 Histopathological changes after multiple challenges of PM-b. A Experimental schedule. PM-b or PBS were intratracheally injected on
days 0, 3, and 7. Mice were euthanized on day 10 (PBS injected mice: n = 5; PM-b injected mice: n = 10) or day 28 (PBS injected mice: n = 5; PM-b
injected mice: n = 8). B, C Representative images of the lung of mice on days 10 (B) and 28 (C). Pulmonary histopathological changes were
evaluated by three different types of stainings (HE: Hematoxylin-Eosin staining; MT: Masson’s Trichrome staining; SR: Sirius Red staining). Scale
bar: 100 μm
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inflammation or lung fibrosis were induced. Similar re-
sults were observed in the lungs of mice sacrificed at day
14 (Fig. 3B).
It was therefore confirmed that a single intratracheal
injection of PM-b is insufficient to induce lung damage.
Studies conducting animal experiments that inject PM
several times to induce lung damage have also been re-
ported [25–27]; hence, we also applied the multiple
challenge model (Fig. 4A). After three doses of intratra-
cheal instillation of PM-b, TEM images revealed the
presence of PM-b particles in the vacuoles of alveolar
macrophages, and also in blood vessels (Fig. 5). Histo-
logical evaluation determined greater PM-b accumula-
tion in lung tissues after three doses of intratracheal
instillation of PM-b, and more macrophages with PM-b
containing vacuoles were observed. Although there was
evidence of mild to moderate lung inflammation, such
as thickening of alveolar walls and infiltration of in-
flammatory cells, there were no findings of pulmonary
fibrosis (Fig. 4B, C).
In the previous two animal experiments (single
challenge model and multiple challenges model), only
PM-b alone was unable to reproduce lung damage ac-
companied by lung fibrosis. In addition, in studies with
repeated intratracheal injections, the results tended to
depend significantly on the experimenter’s proficiency in
surgical processes. It has recently been reported that PM
contributes to increasing the lung damage in patients
with underlying diseases such as COPD and asthma
[28]. We therefore performed the OVA-PM model to
confirm lung damage caused by PM-b, and simultan-
eously reducing the difference between experimenters by
minimizing invasive processes (Fig. 6A).
Notable histological features in asthmatic patients in-
clude mucous hypersecretion, fibrosis in subepithelial re-
gion, inflammatory cell infiltration, and hypertrophy of
bronchial smooth muscle [29]. These histopathological
changes in asthma are mainly mediated by IgE, since
asthma is a type I hypersensitivity reaction [30]. In the
animal experiment applying the OVA-PM model, in-
creased PAS positive cells and peribronchial infiltration
of inflammatory cells were observed in the OVA-
induced asthma models (Fig. 6B, OVA). Also, signifi-
cantly higher levels of serum total IgE were detected, as
compared to the control group (Fig. 6C, OVA). Further-
more, not only peribronchial inflammation was more se-
vere, but the number of PAS positive cells was increased
in mice exposed to PM-b after inducing asthma, than
mice of the OVA group. The total IgE level in serum
also tended to increase in the combined treatment as
compared to the only OVA group (Fig. 6B, C). Depos-
ition of collagen was slightly increased after OVA treat-
ment, but there was no significant differences between
OVA and OVA+PM group (Fig. 6B).
Fig. 5 Transmission electron microscopy images of lungs treated with PM-b. At day 28, some parts of the lung tissues were fixed and
subjected to TEM. PM-b particles were observed in alveolar macrophages and alveolar capillaries. P: vacuoles containing PM-b particles; M:
alveolar macrophage; C: alveolar capillary; Arrow: pinocytotic vesicle; Arrowhead: mitochondria. Scale bar: 20,000 nm and 2000 nm in low and
high magnification images, respectively
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Fig. 6 (See legend on next page.)
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Previous studies have reported that the profile of
inflammatory cells in bronchoalveolar lavage fluid
(BALF) is altered after PM exposure [26], and inflam-
matory cytokines such as tumor necrosis factor alpha
(TNF-α), interleukin 1 beta (IL-1β), and interleukin 6
(IL-6) are increased in BALF of mice treated with PM
[31–33]. However, the above findings from BALF ana-
lysis are more meaningful when histopathological
changes occur simultaneously; hence, in the present
study, we focused on inflammatory and fibrous lesions
caused by PM.
As an in vivo model to study the mechanism of PM-
induced lung injury, it was observed that it is difficult to
reproduce lung diseases by intratracheal instillation of
PM alone. Therefore, we recommend the OVA-PM
model established in this work as an appropriate animal
model, for studying the adverse effects of PM.
Conclusions
In conclusion, this study establishes a method to pre-
pare PM dispersion and a PM-induced lung injury
model for in vivo studies, to verify the effects of PM
exposure on lungs in mice. PM-b was generated by
sonicating SRM2975, followed by addition of tween
80 as an adjuvant. This preparation produces higher
intracellular ROS in MLE 12 cells than other PM dis-
persions. Based on the results from animal experi-
ments, it was found that a single intratracheal
instillation of PM-b is insufficient to induce lung in-
flammation in mice. Also, no significant pulmonary fi-
brosis was observed after multiple PM challenges,
even up to three doses. However, PM-b aggravated
the OVA-induced asthma in the OVA-PM model.
Therefore, we suggest that intratracheal instillation of
PM in the presence of underlying diseases is poten-
tially a suitable animal model for studying molecular
biological mechanisms of PM-induced lung injury,




Diesel particulate matter SRM 2975 was purchased
from the National Institute of Standards and
Technology (NIST, Gaithersburg, USA). The MLE 12
murine type II pneumocyte cell line was obtained
from ATCC (Manassas, VA, USA). The fluorogenic
dye 2́,7́-dichlorodihydrofluorescein diacetate (DCFH-
DA), ovalbumin (OVA) and aluminum hydroxide
(Al(OH)3) were purchased from Sigma-Aldrich (St
Louis, MO, USA). Primary antibodies were purchased
from several vendors: COX-2 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), HO-1 (R&D systems,
Minneapolis, MN, USA), pSTAT3, pP65, and LC3A/B
(Cell Signaling Technology, Danvers, MA, USA), and
GAPDH (Merck Millipore, Darmstadt, Germany).
Glutaraldehyde, paraformaldehyde, and absolute etha-
nol were obtained from Merck Millipore, osmium tet-
roxide (OsO4) was obtained from Polysciences
(Warrington, PA, USA), and 99% pure propylene
oxide was obtained from Acros Organics (99% pure,
Morris Plains, NJ). ELISA kits for mouse serum IgE
were purchased from eBioscience (San Diego, CA,
USA).
Preparation and size analysis of PM dispersions
Prior to making PM-a and PM-b, SRM2975 was dis-
persed in phosphate buffered saline (PBS) at a final
concentration of 2.5 mg/ml (PM-PBS). For making
PM-a, the PM-PBS was sonicated in a bath sonicator
for 30 min and probe sonicator for 20 s. PM-b was
made by mixing PM-a with tween 80 at 0.05% (v/v).
All dispersions were stored at − 20 °C, until further
use. Size analysis of PM dispersions was conducted by
a zeta potential and particle size analyzer (ELSZ-1000,
Otsuka Electronics CO, Osaka, Japan), as previously
described [34]. Briefly, each PM dispersion was di-
luted 1:100 in PBS to a total volume of 1 ml. The
mean diameter, polydispersity index (P.I.), and num-
ber distribution were subsequently measured for the
particles contained in each dispersion, and this pro-
cedure was repeated five times for each dispersion.
Cell cultures
MLE 12 cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 2% (v/v)
fetal bovine serum (FBS) and penicillin/streptomycin
(See figure on previous page.)
Fig. 6 Histopathological changes in the lungs of mice obtained from the OVA-PM model. A Experimental schedule. OVA or PBS were
intraperitoneally injected on days 0, 7, and 14. Thereafter, ovalbumin or PBS were intranasally inoculated on days 21 and 22, followed by
intratracheally injection of PM-b or PBS on day 23. All mice were euthanized on day 30 (CON group: n = 5; OVA group: n = 6; OVA+PM group: n =
5). B Representative images of the lungs of mice at the day of autopsy. Infiltration of inflammatory cells were observed in the OVA group and
OVA+PM group (Red arrow head on the HE staining). The number of infiltrated cells were increased in the OVA+PM group, as compared to the
OVA group. The number of PAS positive cells were greater in lungs obtained from the OVA+PM group than the OVA group (Red arrow on the
PAS staining). Scale bar: 100 μm. C Serum total IgE of all mice was measured by ELISA and compared between groups. The bar graphs are
presented as mean ± standard error of mean. One-way ANOVA test was used for statistical analysis. * p < 0.05, ** p < 0.01
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(Welgene, Daegu, Korea). For all in vitro studies de-
scribed below, MLE 12 cells were seeded in 12-well and
6-well cell culture plates at a cell seeding density of 5 ×
105 cells per well and 1 × 106 cells per well, respectively.
Next day, the cells were washed with PBS and exposed
to 100 μg/ml PM for the indicated hours. The treated
MLE 12 cells were then subjected to intracellular react-
ive oxygen species (ROS) measurement or Western
blotting.
Intracellular ROS measurement
Intracellular ROS was measured using DCFH-DA, as
previously described [35]. Briefly, MLE 12 cells were
treated with PM for 30min, followed by staining with
DCFH-DA (2.5 μM) for 20 min. After staining, the cells
were washed with PBS and harvested. The harvested
cells were centrifuged at 1400 rpm for 3min, and the cell
pellet was washed with PBS and re-centrifuged. The
washed cell pellet was resuspended in PBS and subjected
to flow cytometry for measuring intracellular ROS.
Western blotting
MLE 12 cells were exposed to PM-b for 3, 6, 9, 24, or
48 h, and the total protein obtained was subjected to
Western blotting. Briefly, the PM treated cells were lysed
with radioimmunoprecipitation assay (RIPA) buffer and
the total protein was extracted. Quantification of the ex-
tracted protein was performed, and identical amounts of
protein were separated by SDS-PAGE. The proteins on
SDS-PAGE gel were transferred to polyvinylidene fluor-
ide membranes, followed by blocking the membranes
with 5% (w/v in TBS-T) skim milk. After washing,
blocked membranes were incubated with the respective
primary antibodies, overnight at 4 °C. Next day, the pri-
mary antibody conjugated membranes were incubated
with the secondary antibody for 1 h. Detection of the im-
munoreactive bands was performed using Absignal
(Abclon, Seoul, Korea).
In vivo experiments
For animal experiments, ICR and BALB/c male mice
were purchased from Orient Bio (Seungnam, Korea). All
animal experiments were conducted at Gachon Univer-
sity, in accordance with the procedures approved by the
Institutional Animal Care and Usage Committee
(IACUC) (GIACUC-R2020020–1). For this study, we
conducted three animal experiments: (1) PM single chal-
lenge model, (2) PM multiple challenges model, and (3)
PM challenge with ovalbumin (OVA)-induced asthma
(OVA-PM) model.
(1) PM single challenge model
Seven-week-old male ICR mice were acclimated for 1
week, and all mice were exposed to PM-b at 250 μg/
mouse through intratracheal (i.t.) injection, as previously
described (day 0) [36]. Mice were euthanized at day 7
(n = 5) and day 14 (n = 5).
(2) PM multiple challenges model
Seven-week-old male ICR mice were randomly divided
into two groups after 1 week acclimation; each group
was exposed to either PBS or PM-b (250 μg/mouse),
through i.t. injection on days 0, 3, and 7. Mice were eu-
thanized on day 10 (PBS injected mice: n = 5; PM-b
injected mice: n = 10) or day 28 (PBS injected mice: n =
5; PM-b injected mice: n = 8).
(3) PM challenge with ovalbumin (OVA)-induced
airway inflammation (OVA-PM) model.
Seven-week-old male BALB/c mice (n = 16) were pur-
chased from Orient Bio (Seongnam, Korea). Mice were
randomly divided into three groups after acclimation for
1 week (CON group: n = 5; OVA group: n = 6; and
OVA+PM group: n = 5). Mice of OVA and OVA+PM
groups were sensitized with 10 μg OVA emulsified in
1.5 mg Al(OH)3 in 200 μl of PBS, through intraperitoneal
injection, on days 0, 7, and 14. Mice of the OVA and
OVA+PM groups were anesthetized by intraperitoneal
injection of Avertin (20 mg/kg), and challenged with 2%
(w/v) OVA solution, 25 μl per nostril per mouse on days
21 and 22. On day 23, mice of the OVA+PM group were
exposed to PM-b at 250 μg/mouse by administering an
i.t. injection, while mice of the OVA group were exposed
to only PBS. Mice of the CON group received only PBS
on the same day through the same route. All mice were
euthanized at day 30.
On the day of autopsy in all three experiments, blood
was collected through cardiac puncture, and the serum
was separated from each blood sample. The lungs were
perfused with sterile PBS, and subsequently harvested
for histological examination.
Histological examination
To investigate histopathological changes, the lungs were
harvested on the day of autopsy and fixed in 10% neutral
buffered formalin, followed by embedding in paraffin
blocks. The paraffin blocks were then sectioned at 5 μm-
thick slices. All lung sections were subjected to HE
staining to evaluate the severity of alveolar wall thickness
and inflammatory cells infiltration. MT and SR staining
were also performed to evaluate fibrotic changes in re-
sponse to PM exposure. PAS staining was conducted to
compare the severity of mucous hypersecretion in lungs
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of mice of the OVA-PM model. Each stained section
was observed under light microscope.
Transmission Electron Microscopy (TEM)
Specimens for transmission electron microscopy were
fixed for 12 h in 2% glutaraldehyde-2% paraformaldehyde
prepared in 0.1M phosphate buffer (pH 7.4), subse-
quently washed in 0.1M phosphate buffer, post-fixed
with 1% OsO4 in 0.1M phosphate buffer for 2 h, and
dehydrated with an ascending ethanol series (50, 60, 70,
80, 90, 95, 100, 100%) for 10 min each, followed by infil-
tration with propylene oxide for 10 min. Specimens were
embedded with a Poly/Bed 812 kit (Polysciences), and
polymerized in an electron microscope oven (TD-700,
DOSAKA, Japan) at 65 °C for 12 h. The block subse-
quently cut into 200 nm semi-thin section using a dia-
mond knife in the ultramicrotome. Then, the sections
were stained with toluidine blue and observed under an
optical microscope. The region of interest was then cut
into 80 nm thin sections using the ultramicrotome. The
sections were placed on copper grids and double stained
with 3% uranyl acetate and 3% lead citrate for 30 min
and 7min, respectively. The stained sections were then
imaged with a transmission electron microscopy (JEM-
1011, JEOL, Tokyo, Japan) equipped with a Megaview III
CCD camera (Soft imaging system-Germany), at an ac-
celeration voltage of 80 kV.
Serum IgE enzyme-linked immunosorbent assay (ELISA)
Total serum IgE levels were detected using the commer-
cially available ELISA kit, following the manufacturer’s
recommendation. The serum samples were diluted (1:
25) and subjected to IgE ELISA.
Statistical analysis
To compare serum IgE levels between groups, One-way
ANOVA test was used for statistical analysis. Experi-
mental data are expressed as mean ± standard error of
mean.
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